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Abstract
Background: Human dermal allografts have been used for over a decade for interpositional repair of rectoceles.
How do dermal allografts perform with regards to success rate and complications with 8 years’ minimum follow-up?
Methods: We retrospectively reviewed 41 consecutive patients undergoing dermal allograft interposition procedures
between October 2001 and December 2005 (Repliform, Boston Scientific, Natick, MA, USA) for stage two, three, and
four International Continence Society (ICS) symptomatic rectocele repairs with bilateral sacrospinous fixation. Failure
was defined as recurrent stage two International Continence Society prolapse (Ap≥ −1 and/or Bp≥ −1). All
questionnaires were completed 1 week before surgery and at follow-up (September 2014 through December 2014).
Results: The mean preoperative and postoperative A(p) were 0.95 ± 0.70,−1.90 ± 0.52 and B(p) 1.30 ± 0.84,−2.13 ± 0.51
(p < 0.001). With a mean follow-up of 116.5 ± 18.9 months, a success rate of 73 % (30/41) was achieved, with
anatomical reduction of prolapse. For splinting and digitations, an 82 % cure rate was realized. The Pelvic Floor Distress
Inventory (PFDI) pre- and post-operative results showed significant improvement (p < 0.001). There were two incisional
exposures (5 %). Seventy percent of patients were secondary repairs while 30 % were primary repairs (81 % success
rate, p < 0.36). One patient experienced nerve entrapment and subsequent unilateral takedown. Patient satisfaction was
77 %.
Conclusions: Our retrospective study approaching long-term results demonstrated that symptomatic rectocele
procedures with human dermal allograft interposition provide an effective anatomical and functional repair with
acceptable complication rates.
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Background
Pelvic organ prolapse is a common surgical women’s
health care issue affecting over ten million American
women, at a projected cost of two billion dollars (USD)
each year [1]. Approximately 12 % of adult women will
eventually require surgical therapy for their symptomatic
prolapse [2]. Prolapse is the result of a multitude of mo-
lecular and physiological changes that cause weakening
in one or more supportive structures in the pelvic com-
partment. Rectal protrusions are attributed to connective
tissue defects in the rectovaginal fascia that are level two
Delancey pelvic support mechanisms. The most com-
monly used surgical procedures for repair in this area
involve suture ligation with native tissue plication [3]. An-
other method of rectocele repair is defect-specific re-
approximation of the rectovaginal fascia without levator
plication [4, 5]. This procedure results in less post-
operative pain but not much improvement in reduced
rectocele recurrence.
Practitioners have tended to agree that, in the instance
of transvaginal organ prolapse repairs, patients’ innate
connective tissue defects can be repaired with the inter-
position of biologic human allograft dermal material [6, 7]
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or synthetic materials such as polypropylene [8]. Today,
these biologic materials [9] abound, yet long-term studies
are lacking. Available studies have multitudes of clinical
criteria for evaluation and measurements for failure, mak-
ing comparisons inaccurate and difficult to assess. Clinical
assessments are often retrospective and include a variety of
surgical approaches, so clear-cut evaluations and critiques
regarding usefulness remain unclear.
Synthetic materials categorized via the Amid [10] (1997)
five-material classification system have been applied to
what was originally used for general surgeons’ herniorrha-
phy procedures and are now also applied to female pelvic
prolapse surgeries (Table 1). Materials are separated into
macroporous, microporous, or both, and include three
well-studied materials: polypropylene, mersilene and poly-
tetrafluoroethylene. In 2011, the Federal Drug Administra-
tion issued a stern warning against the transvaginal
utilization of synthetic materials, prompting a voluntary
removal of several pelvic floor reconstruction products
from the market (i.e., Prolift, Gynecare, Somerset, New
Jersey). As a result, surgeons were left with fewer options
for transvaginal prolapse repairs. For more than 12 years,
we have extensively used dermal allograft materials (Repli-
form, Boston Scientific, Natick, Massachusetts, USA) for
symptomatic rectocele repairs with bilateral sacrospinous
fixation [11–14] and now report our minimum eight-year
follow-up experience with this human allograft product.
Methods
Between October 2001 and December 2005, we performed
41 consecutive symptomatic repairs with human dermal
allograft interposition and bilateral sacrospinous fixation for
stage two, three, or four International Continence Society
rectoceles, with or without digitation and/or splinting. All
rectoceles were performed with suture ligation of the new
human dermal allograft fascia to the rectovaginal fascia
with bilateral sacrospinous fixation. Surgeries were
performed in their entirety by the first author. The Caprio
device [11] (Boston Scientific, Natick, MA, USA) was used,
with 0-polypropylene sutures (two sutures applied to the
right sacrospinous ligament and another two to the left
ligament). Failure was defined as recurrent International
Continence Society stage two or more prolapses. All pa-
tients underwent a complete history and physical examin-
ation with International Continence Society prolapse (POP)
scoring. Urodynamics were performed only if the patient
was also undergoing a concomitant continence procedure
performed with a tension-free vaginal tape (TVT, Gynecare,
Somerset, New Jersey), tension-free vaginal tape obturator
(TVTO, Gynecare, Somerset, New Jersey) or tension-free
vaginal tape-Secur (Gynecare, Somerset, New Jersey, USA).
Urodynamic results are not included in this study. All pre-
operative and postoperative data were collected between
September 2014 and December 2014. Our research was
performed in accordance with the Declaration of Helsinki
and was approved by the Harper Hospital Institutional
Review Board (Study #033512MP4E). The Pelvic Floor
Distress Inventory-20 (PFDI) [15] and the 7 point Likert
Visual Analogue Scale questionnaire were used to object-
ively determine patient satisfaction and improvement of
symptoms following surgery. On the Likert Scale (Table 2),
only levels of five, six and seven were recorded as satisfac-
tory outcomes. Levels 1–4 were recorded as unsuccessful
outcomes. All patients included their age, parity, body mass
index, smoking status, menopausal, hormone therapy, and
prior pelvic surgery. All exposures were treated the same,
with two grams of topical estrogen thrice weekly for
6 weeks. Follow-up examinations were performed by an
unaffiliated, board-certified gynecologist with 30 years of
experience, who was well acquainted with POPQ staging
and scoring. Statistical analyses were performed using the
Statistical Package for Social Sciences, version 11.0 (SPSS,
Chicago, Illinois). Analyses included simple means, me-
dians, and chi square comparisons.
Results and discussion
The mean preoperative and postoperative A(p) were
0.95 ± 0.70,−1.90 ± 0.52 and B(p) 1.30 ± 0.84,−2.13 ± 0.51
Table 1 Classification of Synthetic Meshes (Amid, 1997)[10]





Type 2: Totally Microporous (port size < 10 μ)
• Goretex






Type 4: Submicronic Pore Size (pore size < 1 μ)
Table 2 Likert Global Response Visual Analogue Scale for Rectocele
Repair
Since having your rectocele repair, please rate your overall rectocele
symptoms:
1. Markedly Worse 1
2. Moderately Worse 1
3. Slightly worse 1
4. Same 1
5. Slightly improved 1
6. Moderately improved 2
7. Markedly improved 3
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(p < 0.001) (Table 3). With a mean follow-up of 116.5 ±
18.9 months, a success rate of 73 % (30/41 patients) was
achieved, with the anatomical reduction of prolapse to
ICS Stage 2 or less (Ap ≥ −1 and/or Bp ≥ −1). For splint-
ing and digitation elimination, an 82 % cure rate was
realized (15/18). In the follow-up period, 13 % (3/23) of
patients complained of de novo splinting. First-time
repairs demonstrated an 81 % anatomical success rate while
secondary repairs detailed a 70 % anatomical repair. Seventy
percent were secondary repair, with a 70 % success rate
while 30 % of the patients were primary repairs (81 %
success rate) (p < 0.36). The Pelvic Floor Distress Inventory
(PFDI) pre- and postoperative results showed significant
improvement (p < 0.001). There were three incisional
exposures (7 %) of the human dermal allograft, which
responded to estrogen replacement therapy for 6 to 8 weeks.
One patient experienced rectal outflow obstruction and
another pelvic nerve entrapment, which caused left gluteal
pain. Both required re-operative take down at two and
twenty weeks after rectocele repair. Patient satisfaction was
77 % (Table 3). De novo dyspareunia was 17 %.
A review of rectocele repairs shows that, for a host of
reasons, procedures without augmentation have not been
successful. Pelvic floor remodeling of the supportive con-
nective tissue continues to occur, with increased activity
of collagenase and elastase enzymes [16, 17]. Elastase deg-
radation leads to decreased connective tissue flexibility
and expansion [18]. Together, these biologically enzyme
processes lead to a potentially weaker pelvic floor infra-
structure [18].
Native tissue amended with suture ligation and/or fix-
ation to autologous ligaments or bone may lead to compro-
mised clinical results because of the continual exposure to
connective tissue remodeling [19–22]. Surgical treatment
has seen the development of many transvaginal synthetic
pelvic floor prolapse repair kits [23]. These kits have not
fared as well as transvaginal stress incontinence instru-
ments and materials, which are made of similar synthetic
materials but with a more limited exposure area. [24] While
stress incontinence kits are not exempt from failure or
complications including exposure or erosion into the vagina
or pelvic organ, in the past 5 years, prolapse repair kits have
found themselves at the forefront of malpractice litigation.
In the early 2000’s several studies with the biological xeno-
graft (porcine) product Pelvichol [25] (C.R. Bard, Inc.
Murray Hill, New Jersey, USA) demonstrated hastened re-
absorption by the body and left pelvic floor surgeons much
less enthusiastic towards its use. However, experience with
human dermal allograft in 2000 gave us adequate two-year
and four-year data for rectocele repairs [5, 6] while we still
used abdominal sacrocolpopexy for all multi-compartment
prolapse repairs. Approaching 10 years’ follow-up (116.5 ±
18.9 months), a good success rate can be attributed to a
lasting biological material and augmentation of the poster-
ior pelvic floor compartment with a concomitant bilateral
sacrospinous fixation with permanent suture. Limitations
of our study included two major complications: the unilat-
eral takedown of the rectocele repair/augmentation because
of rectal outflow obstruction, and pelvic nerve entrapment,
which required a unilateral takedown. These complications
combined with three vaginal exposures gave us a com-
plication rate of 12 %. Both patients were morbidly
obese, less than five feet tall, with body mass index
scores of 40 and 41.
The 11 patients who failed their surgery had a mean
time to failure of 24.7 ± 15.3 months. At the time of their
sacrocolpopexy, we carefully examined the pelvic com-
partment for the human dermal allograft. Quantities of
tissue were still found circumscribing the periphery of
the rectovaginal fascia, but the attachment to the poly-
propylene suture had, in most cases, pulled through
from the sacrospinous ligament and/or the tissue was
tattered in appearance. Of these 11, eight elected to have
surgery to repair their rectoceles, but because the pro-
lapse now involved more than one compartment, six of
Table 3 Patient Demographics (n = 41)
Mean Age (yrs) 60.6 ± 16.3
Mean Follow-up (months) 116.5 ± 18.9
Mean Parity 2.6 ± 2.37




Hormone Replacement (percent) 40.9
Sexually active (percent) 24.1
Previous Pelvic Surgery (percent) 70.0
Mean Preoperative A (p)(centimeters)a 0.95 ± 0.70
Mean Postoperative A (p) (centimeters)a −1.90 ± 0.52
Mean Preoperative B (p)(centimeters)a 1.30 ± 0.84
Mean Postoperative B (p)(centimeters)a −2.13 ± 0.51
Mean PreOp PFDI-20 (/300)a 129.6 ± 26.7 (78–223)
Mean PostOp PFDI-20 (/300)a 60.9 ± 18.4 (32–108)
Biological erosion (percent) 7.3
De novo dyspareunia (percent) 17.0
Complication rate (percent) 12.1
Patient satisfaction (percent)b 77.0
Prolapse Failure Rate (percent)c 27.0
Time to Prolapse Failure (months) 24.7 ± 15.3
aChanges between pre- and postoperative Pelvic Floor Distress Inventory
(PFDI-20, n = 41) and A(p) and B(p) were statistically significant at p = <0.001 at
the time of patients’ last follow-up
bA 7 point Likert Global Response Scale was used, whereby responses five, six
and seven were deemed successful. Numbers 1–4 were judged as failures. The
77 % satisfaction rate includes only the former and not the latter
cEleven prolapse failures: 7 Stage 2 (ICS), 3 Stage 3, and 1 Stage 4
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the eight elected to undergo sacrocolpopexy with anter-
ior and posterior polypropylene mesh interposition.
Encouraging factors for the utilization of human dermal
allograft include its good anatomical reduction of the recto-
cele, as well as symptom improvement with a follow-up in
many cases exceeding 10 years. This efficacy can be consid-
ered a driving force for its continued utilization in the
posterior compartment symptomatic rectocele repair; how-
ever, Level 1 and/or Level 2–1 evidence studies should be
conducted to better compare the efficacy and safety of
human dermal allograft to other pelvic floor materials.
Conclusions
Our retrospective study demonstrated that rectocele repairs
with biological augmentation and bilateral sacrospinous
fixation with a minimum 8 years’ follow-up provide a good
anatomical and functional repair with an acceptable com-
plication rate.
Brief summary
Human dermal allograft interposition repair of rectoceles
can be used safely and successfully, with good patient sat-
isfaction in follow-up periods approaching 10 years.
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